AgeX Therapeutics Inc. (AGE) and Tyme Technologies Inc. (NASDAQ:TYME) Comparison side by side

AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and Tyme Technologies Inc. (NASDAQ:TYME) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AgeX Therapeutics Inc. 2 0.00 15.32M -0.29 0.00
Tyme Technologies Inc. 1 0.00 53.08M -0.32 0.00

Table 1 demonstrates AgeX Therapeutics Inc. and Tyme Technologies Inc.’s gross revenue, earnings per share and valuation.


Table 2 demonstrates the return on assets, return on equity and net margins of AgeX Therapeutics Inc. and Tyme Technologies Inc.

Net Margins Return on Equity Return on Assets
AgeX Therapeutics Inc. 1,001,896,540.45% -109.8% -85.5%
Tyme Technologies Inc. 4,250,820,853.69% -193.3% -153.7%


4.2 and 4.2 are the respective Current Ratio and a Quick Ratio of AgeX Therapeutics Inc. Its rival Tyme Technologies Inc.’s Current and Quick Ratios are 2.6 and 2.6 respectively. AgeX Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Tyme Technologies Inc.

Insider and Institutional Ownership

AgeX Therapeutics Inc. and Tyme Technologies Inc. has shares owned by institutional investors as follows: 23.5% and 20%. Insiders owned 0.2% of AgeX Therapeutics Inc. shares. Comparatively, insiders own roughly 47.4% of Tyme Technologies Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AgeX Therapeutics Inc. 31.39% -12.28% -35.18% -25.45% 0% -2.01%
Tyme Technologies Inc. -10.57% -6.78% -26.17% -60.43% -61.67% -70.19%

For the past year AgeX Therapeutics Inc. was less bearish than Tyme Technologies Inc.


AgeX Therapeutics Inc. beats on 6 of the 9 factors Tyme Technologies Inc.

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.